A Phase I, Single Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Tolerability of C1 Inhibitor (CINRYZE) as a Donor Pre-treatment Strategy in Brain Dead Donors Who Meet a Kidney Donor Risk Index (KDRI) Above 85%
Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 03 Oct 2017
At a glance
- Drugs Complement C1 inhibitor protein (Primary) ; Heparin
- Indications Renal failure
- Focus Therapeutic Use
- 03 Oct 2017 Last checked against ClinicalTrials.gov record.
- 28 Sep 2017 Planned End Date changed from 1 Dec 2018 to 1 May 2020.
- 28 Sep 2017 Planned primary completion date changed from 1 Apr 2018 to 1 May 2019.